Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

A clinical trial involving 778 hospitalized COVID-19 patients tested the efficacy of proxalutamide, an anti-androgen drug. The patients were randomly given either proxalutamide 300mg/day or a placebo for 14 days. The recovery rate was 121% higher in the proxalutamide group than the placebo group at day 14, and 81% higher at day 28. The all-cause mortality rate was 80% lower in the proxalutamide group than the placebo group at Day 14, and 78% lower at Day 28. The time-to-discharge was shorter in the proxalutamide group (median, 5 days) than the placebo group (median, 9 days). The results were consistent across different regions and genders. The study concluded that proxalutamide significantly improved recovery rates, reduced mortality rates, and shortened hospital stay in hospitalized COVID-19 patients. However, further trials are recommended to confirm these findings.